Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by priceless2on Oct 19, 2012 4:19pm
255 Views
Post# 20504670

RE: RE: Morgan Stanley and Goldman Sachs

RE: RE: Morgan Stanley and Goldman Sachs

As we get closer to Assure top line data I think we will slowy move up with the anticiapation of good results However if we get  a large media publication in a major newspaper or magazine we could see a huge quick spike in the SP in the short turn.  All we need is some good press and we should see this stock fly.

My immediate question is if there is some planning currently going on in designing a phase 3 trial with the help and or assistance of BP, then would that not be material information that us shareholders should be informed in a PR.  Inquiring minds want to know who and what involvement BP has to this point.

SF statement of RVX management " keeping there cards to thir chest"  is getting really annoying" If they would just do more tweaking in there PR I think the stock would move much faster

 

 

Bullboard Posts